The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Open accessAbstract
Purpose: Multiple-gene sequencing is entering practice, but its clinical value is unknown. We evaluated the performance of a customized germline-DNA sequencing panel for cancer-risk assessment in a representative clinical sample. Methods: Patients referred for clinical BRCA1/2 testing from 2002 to 2012 were invited to donate a research blood sample. Samples were frozen at −80° C, and DNA was extracted from them after 1 to 10 years. The entire coding region, exon-intron boundaries, and all known pathogenic variants in other regions were sequenced for 42 genes that had cancer risk associations. Potentially actionable results were disclosed to participants. Results: In total, 198 women participated in the study: 174 had breast cancer and 57 carried germline BRCA1/2 mutations. BRCA1/2 analysis was fully concordant with prior testing. Sixteen pathogenic variants were identified in ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4 among 141 women without BRCA1/2 mutations. Fourteen participants carried 15 pathogenic variants, warranting a possible change in care; they were invited for targeted screening recommendations, enabling early detection and removal of a tubular adenoma by colonoscopy. Participants carried an average of 2.1 variants of uncertain significance among 42 genes. Conclusion: Among women testing negative for BRCA1/2 mutations, multiple-gene sequencing identified 16 potentially pathogenic mutations in other genes (11.4%; 95% CI, 7.0% to 17.7%), of which 15 (10.6%; 95% CI, 6.5% to 16.9%) prompted consideration of a change in care, enabling early detection of a precancerous colon polyp. Additional studies are required to quantify the penetrance of identified mutations and determine clinical utility. However, these results suggest that multiple-gene sequencing may benefit appropriately selected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., McGuire, A. L., Nussbaum, R. L., O’Daniel, J. M., Ormond, K. E., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.73 · Cited by 2,541
Human non-synonymous SNPs: server and survey
Ramensky, V. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf493 · Cited by 2,280
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationPrediction of deleterious human alleles
Sunyaev, S. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.6.591 · Cited by 1,044
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
The Breast Cancer Susceptibility Collaboration (UK), Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., et al. (2007) · Nature Genetics · doi:10.1038/ng1959 · Cited by 1,003
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Self-citationLifetime Cancer Risks in Individuals with Germline PTEN Mutations
Tan, M.-H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., & Eng, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2283 · Cited by 892
Multiple Colorectal Adenomas, Classic Adenomatous Polyposis, and Germ-Line Mutations in MYH
Sieber, O. M., Lipton, L., Crabtree, M., Heinimann, K., Fidalgo, P., Phillips, R. K. S., Bisgaard, M.-L., Orntoft, T. F., Aaltonen, L. A., Hodgson, S. V., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025283 · Cited by 862
Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome
Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J. P., Keller, J. J., Westerman, A. M., Scott, R. J., Lim, W., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0083 · Cited by 855
Richards, C. S., Bale, S., Bellissimo, D. B., Das, S., Grody, W. W., Hegde, M. R., Lyon, E., & Ward, B. E. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31816b5cae · Cited by 832
The Breast Cancer Susceptibility Collaboration (UK), Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., Jayatilake, H., Ahmed, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1902 · Cited by 746
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
The Breast Cancer Susceptibility Collaboration (UK), Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., North, B., Jayatilake, H., Barfoot, R., et al. (2006) · Nature Genetics · doi:10.1038/ng1837 · Cited by 743
Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund, M., Lichtner, P., Hartmann, L., Schaal, H., et al. (2010) · Nature Genetics · doi:10.1038/ng.569 · Cited by 743
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Self-citationPharoah, P. D. P., Guilford, P., & Caldas, C. (2001) · Gastroenterology · doi:10.1053/gast.2001.29611 · Cited by 638
Lemmens, I. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.7.1177 · Cited by 611
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., Nord, A. S., Mandell, J. B., Swisher, E. M., & King, M.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007983107 · Cited by 487
Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer
Kaurah, P., MacMillan, A., Boyd, N., Senz, J., De Luca, A., Chun, N., Suriano, G., Zaor, S., Van Manen, L., Gilpin, C., et al. (2007) · JAMA · doi:10.1001/jama.297.21.2360 · Cited by 447
Self-citationRobson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0660 · Cited by 421
Kong, W., He, L., Richards, E. J., Challa, S., Xu, C.-X., Permuth-Wey, J., Lancaster, J. M., Coppola, D., Sellers, T. A., Djeu, J. Y., et al. (2014) · Oncogene · doi:10.1038/onc.2012.636 · Cited by 417
STRIDE--An integrated standards-based translational research informatics platform.
Lowe, H., Ferris, T., Hernandez, P. M., & Weber, S. (2009) · PubMed · Cited by 397
Variants in DNA double-strand break repair genes and breast cancer susceptibility
Kuschel, B. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.12.1399 · Cited by 387
Hall, M. J., Reid, J. E., Burbidge, L. A., Pruss, D., Deffenbaugh, A. M., Frye, C., Wenstrup, R. J., Ward, B. E., Scholl, T. A., & Noll, W. W. (2009) · Cancer · doi:10.1002/cncr.24200 · Cited by 365
ACR Appropriateness Criteria Breast Cancer Screening
Mainiero, M. B., Lourenco, A., Mahoney, M. C., Newell, M. S., Bailey, L., Barke, L. D., D'Orsi, C., Harvey, J. A., Hayes, M. K., Huynh, P. T., et al. (2013) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2012.09.036 · Cited by 342
Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., Boland, C. R., Ford, J., Elkin, E., & Phillips, K. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-2-201107190-00002 · Cited by 340
Self-citationPilarski, R., & Eng, C. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.018036 · Cited by 329
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280
Risks of Primary Extracolonic Cancers Following Colorectal Cancer in Lynch Syndrome
Win, A. K., Lindor, N. M., Young, J. P., Macrae, F. A., Young, G. P., Williamson, E., Parry, S., Goldblatt, J., Lipton, L., Winship, I., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs351 · Cited by 254
Relative frequency and morphology of cancers in STK11 mutation carriers1 ☆
Lim, W., Olschwang, S., Keller, J. J., Westerman, A. M., Menko, F. H., Boardman, L. A., Scott, R. J., Trimbath, J., Giardiello, F. M., & Gruber, S. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.014 · Cited by 254
Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?
Domchek, S. M., Bradbury, A., Garber, J. E., Offit, K., & Robson, M. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9403 · Cited by 237
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Palladin Mutation Causes Familial Pancreatic Cancer and Suggests a New Cancer Mechanism
Pogue-Geile, K. L., Chen, R., Bronner, M. P., Crnogorac-Jurcevic, T., Moyes, K. W., Dowen, S., Otey, C. A., Crispin, D. A., George, R. D., Whitcomb, D. C., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030516 · Cited by 215
Mutations associated with variant phenotypes in ataxia-telangiectasia.
McConville, C. M., Stanković, T., Byrd, P. J., McGuire, G. M., Yao, Q. Y., Lennox, G. G., & Taylor, A. M. R. (1996) · PubMed Central · Cited by 196
Suriano, G. (2003) · Human Molecular Genetics · doi:10.1093/hmg/12.5.575 · Cited by 180
Nijmegen Breakage Syndrome mutations and risk of breast cancer
Bogdanova, N. V., Feshchenko, S., Schürmann, P., Waltes, R., Wieland, B., Hillemanns, P., Rogov, Y., Dammann, O., Bremer, M., Karstens, J. H., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23168 · Cited by 143
A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis
Sætrom, P., Biesinger, J., Li, S. M., Smith, D., Thomas, L. F., Majzoub, K., Rivas, G. E., Alluin, J., Rossi, J. J., Krontiris, T. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1201 · Cited by 138
Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability
Seemanová, E., Sperling, K., Neitzel, H., Varon, R., Hadač, J., Butova, O., Schröck, E., Seeman, P., & Digweed, M. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.035287 · Cited by 125
Characterization of Mutant MUTYH Proteins Associated With Familial Colorectal Cancer
Ali, M., Kim, H., Cleary, S. P., Cupples, C. G., Gallinger, S., & Bristow, R. G. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.035 · Cited by 100
p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
Reymond, A., & Brent, R. (1995) · PubMed · Cited by 99
Cancer Risk of Heterozygotes With the NBN Founder Mutation
Seemanová, E., Jarolı́m, P., Seeman, P., Varon, R., Digweed, M., Swift, M., & Sperling, K. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm251 · Cited by 96
A common variant of CDKN2A (p16) predisposes to breast cancer: Table 1
Dębniak, T., Górski, B., Huzarski, T., Byrski, T., Cybulski, C., Mackiewicz, A., Gozdecka-Grodecka, S., Gronwald, J., Kowalska, E., Haus, O., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.031476 · Cited by 83
Jatoi, I. (1999) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)00096-3 · Cited by 81
Mitui, M., Nahas, S., Du, L., Yang, Z., Lai, C. H., Nakamura, K., Arroyo, S., Scott, S. P., Purayidom, A., CONCANNON, P. J., et al. (2008) · Human Mutation · doi:10.1002/humu.20805 · Cited by 79
Rouleau, É., Lefol, C., Bourdon, V., Coulet, F., Noguchi, T., Soubrier, F., Bièche, I., Olschwang, S., Sobol, H., & Lidereau, R. (2009) · Human Mutation · doi:10.1002/humu.20947 · Cited by 76
Bai, H. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki209 · Cited by 66
Gene Patents and Personalized Cancer Care: Impact of the Myriad Case on Clinical Oncology
Offit, K., Bradbury, A. R., Storm, C. D., Merz, J. F., Noonan, K. E., & Spence, R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7388 · Cited by 63
Kurian, A. W., Mitani, A., Desai, M., Yu, P. P., Seto, T., Weber, S., Olson, C., Kenkare, P., Gomez, S. L., de Bruin, M. A., et al. (2013) · Cancer · doi:10.1002/cncr.28395 · Cited by 61
Self-citationFunctional reassessment of P16 variants using a transfection-based assay
Walker, G. J., Gabrielli, B. G., Castellano, M., & Hayward, N. K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990719)82:2<305::aid-ijc24>3.0.co;2-z · Cited by 59
FANCP/SLX4: A Swiss army knife of DNA interstrand crosslink repair
Cybulski, K. E., & Howlett, N. G. (2011) · Cell Cycle · doi:10.4161/cc.10.11.15818 · Cited by 57
Soon, W. W., Miller, L. D., Black, M. A., Dalmasso, C., Chan, X. B., Pang, B., Ong, C. W., Salto‐Tellez, M., Desai, K. V., & Liu, E. T. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100150 · Cited by 54
Comprehensive scanning of theATM gene with DOVAM-S
Buzin, C. H., Gatti, R. A., Nguyen, V. Q., Wen, C. Y., Mitui, M., Sanal, Ö., Chen, J. S., Nozari, G., Mengos, A. E., Li, X., et al. (2003) · Human Mutation · doi:10.1002/humu.10158 · Cited by 54
Activating mutation in MET oncogene in familial colorectal cancer
Neklason, D. W., Done, M. W., Sargent, N. R., Schwartz, A. G., Anton‐Culver, H., Griffin, C. A., Ahnen, D. J., Schildkraut, J. M., Tomlinson, G. E., Strong, L. C., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-424 · Cited by 45
Morak, M., Laner, A., Bacher, U., Keiling, C., & Holinski‐Feder, E. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01478.x · Cited by 44
Assessment of SLX4 Mutations in Hereditary Breast Cancers
Shah, S., Kim, Y., Ostrovnaya, I., Murali, R., Schrader, K. A., Lach, F. P., Sarrel, K., Rau‐Murthy, R., Hansen, N. A. L., Zhang, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066961 · Cited by 44
Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study
Bröberg, K., Huynh, E., Engström, K. S., Björk, J., Albin, M. C., Ingvar, C., Olsson, H. L., & Höglund, M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-140 · Cited by 44
Classifying variants of CDKN2A using computational and laboratory studies
Miller, P. J., Duraisamy, S., Newell, J. A., Chan, P. A., Tie, M. M., Rogers, A. E., Ankuda, C. K., von Walstrom, G. M., Bond, J. P., & Greenblatt, M. S. (2011) · Human Mutation · doi:10.1002/humu.21504 · Cited by 38
The Indispensable Role of Professional Judgment in Genomic Medicine
McGuire, A. L., McCullough, L. B., & Evans, J. P. (2013) · JAMA · doi:10.1001/jama.2013.1438 · Cited by 38
Barroso, E., Pita, G., Arias, J. I., Menéndez, P. R., Zamora, P. M., Blanco, M., Benitez, J. J., & Ribas, G. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0439-5 · Cited by 33
Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer
Landwehr, R., Bogdanova, N. V., Antonenkova, N., Meyer, A. A., Bremer, M., Park‐Simon, T., Hillemanns, P., Karstens, J. H., Schindler, D., & Dörk, T. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1681-1 · Cited by 29
Tuckson, R. V., Newcomer, L. N., & Sa, J. M. D. (2013) · JAMA · doi:10.1001/jama.2013.1468 · Cited by 27
Analysis of the Novel Fanconi Anemia GeneSLX4/FANCPin Familial Breast Cancer Cases
Bakker, J. L., van Mil, S. E., Crossan, G. P., Sabbaghian, N., Leeneer, K. D., Poppe, B. G., Adank, M. A., Gille, H., Verheul, H. M. W., Meijers-Heijboer, H. E. J., et al. (2012) · Human Mutation · doi:10.1002/humu.22206 · Cited by 23
Tram, E., Ibrahim-zada, I., Briollais, L., Knight, J. A., Andrulis, I. L., & Özçelik, H. (2011) · Breast Cancer Research · doi:10.1186/bcr2926 · Cited by 18
Wagner, K., Grzybowska, E. A., Butkiewicz, D., Pamuła‐Piłat, J., Pękala, W., Tęcza, K., Hemminki, K., & Försti, A. (2007) · BMC Genetics · doi:10.1186/1471-2156-8-41 · Cited by 6
(2000) · doi:10.1002/(sici)1098-2264(200004)27:4
Cited by
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Self-citationA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J., Hallberg, E., Moore, R., Thomas, A., Lilyquist, J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0424 · Cited by 611
van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., Caldas, C., Chelcun Schreiber, K. E., Hardwick, R. H., Ausems, M. G. E. M., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103094 · Cited by 561
Self-citation
Metadata
- Authors
- Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., McGuire, V., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., Cargill, M., & Ford, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-07-01
- Volume
- 32
- Issue
- 19
- Pages
- 2001-2009
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2095787833
- Cited by
- 485
- References
- 72
- FWCI
- 41.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.